Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Wanbury Ltd. Share Price
Day's Range
Day's Range
Low
₹250.80
High
₹266.35
Price Summary
| Previous Close | ₹252.40 |
|---|---|
| Day's Range | ₹250.80 - ₹266.35 |
| Open | ₹264.50 |
| 52 Week Range | ₹161.50 - ₹320.95 |
| Volume | 1,08,024 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 278.39 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 20.53 |
| TTM EPS (₹) | 12.30 |
| P/E Ratio | 25.19 |
| Book Value(₹) | 13.16 |
| PAT Margin (%) | 5.06 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 35.97 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1720.0 | 5995.14 |
| Expenses | N/A | N/A |
| PBT | 190.54 | 295.51 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 202.56 | 305.3 |
About Wanbury Ltd.
| Founded | 1988 |
|---|---|
| NSE Symbol | WANBURY |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,29,145.05 | 1,787.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,72,988.62 | 6,505.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,49,322.13 | 4,402.20 | 3,140.10 - 3,140.10 |
| Apollo Hospitals Enterprise Ltd. | 1,20,125.61 | 8,354.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,12,149.13 | 1,390.00 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,09,422.92 | 1,086.85 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,06,482.91 | 1,275.00 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,02,996.20 | 2,252.60 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 97,913.19 | 1,006.05 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 97,382.57 | 2,350.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Wanbury informs about award of order
Pursuant to Regulation 30 (6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, Wanbury (WL) has informed the following: 1. Sertraline Form II approval received from ANVISA, BRAZIL. This is in addition to Sertraline hydrochloride Form 1 approval that Wanbury already has. WL currently hold 75% market share for sertraline in Brazil's market. Approval for Form II, will help in further consolidation company's share of business. 2. WL has received approval from one of the largest customers for a special grade of metformin. DC grade with potential business opportunity to be estimated around Rupees 15 crore per annum. Both the API manufacturing sites i.e. Patalganga and Tanuku of WL are continued to be compliant as per cGMP Rules and Regulations.
The above information is a part of company’s filings submitted to BSE.
Laurus Labs informs about AGM
Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Labs has informed that it enclosed the Notice convening the 21st Annual General Meeting (‘AGM’) of shareholders of the Company, scheduled to be held on Thursday, July 2, 2026 at 3.00 pm (IST) through Video Conferencing (‘VC’)/ through Other Audio-Visual Means (‘OAVM’). The Notice of 21st AGM is also available on the Company’s website at www.lauruslabs.com.
The above information is a part of company’s filings submitted to BSE.
Viyash Scientific informs about acquisition
Lupin informs about press release
GlaxoSmithKline Pharmaceuticals informs about letter for weblink for annual report
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Wanbury Ltd. is ₹252.40 as of 2026-06-08.
The market capitalisation of Wanbury Ltd. is ₹882.57 as of 2026-06-08.
The 1-year return of Wanbury Ltd. is 0.00% as of 2026-06-08.
The P/E ratio of Wanbury Ltd. is 25.19 as of 2026-06-09.
The 52-week high and low of Wanbury Ltd. are ₹320.95 and ₹161.50, respectively, as of 2026-06-08.
People Also Ask
Wanbury Ltd. was originally incorporated as Pearl Organics Limited in August 1988. The company adopted the name Wanbury Limited in September 2004. This change reflected its transition into a pharmaceutical manufacturing business with a broader operational scope and growing presence in domestic and international markets.
Wanbury Ltd. is a publicly listed company whose equity shares are traded on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). Being listed on these exchanges allows participation from both retail and institutional investors and ensures compliance with regulatory disclosure and governance standards.
Wanbury Ltd. generates revenue through the manufacturing and sale of Active Pharmaceutical Ingredients (APIs) and pharmaceutical formulations. The company produces and exports medicines used in therapeutic areas such as diabetes management. Its operations include production, research, and distribution across multiple regulated and semi-regulated global markets.
Pradeep Patni serves as the Chief Executive Officer of Wanbury Ltd., having assumed the role in August 2024. He is responsible for overseeing the company’s strategic direction and operations, working alongside Mohan Kumar Rayana, who is the Promoter and Whole-Time Director involved in leadership and governance functions.
Wanbury Ltd. is a pharmaceutical company engaged in the development and manufacturing of APIs and formulations. With over three decades of experience, it operates integrated facilities that support research and production. The company supplies its products to domestic and international markets, including regulated regions across various therapeutic categories.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
